Key facts: Pomerantz LLP filed a class action lawsuit against Cytokinetics on October 6-7, 2025, alleging securities fraud. Investors can apply to be Lead Plaintiff until November 17, 2025.
Menos de 1 minuto de lectura
- Pomerantz LLP filed a class action lawsuit against Cytokinetics on October 6-7, 2025, alleging securities fraud. Investors can apply to be Lead Plaintiff until November 17, 2025.1
- Cytokinetics announced the FDA won't hold an advisory meeting for its aficamten NDA on March 10, 2025, leading to a stock price drop after submitting the NDA without a risk strategy.2